Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the resubmission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) people with multi-drug resistant (MDR) HIV-1 infection. Gilead resubmitted the NDA in response to the FDA Complete Response Letter (CRL) issued in February 2022,

Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor

Gileads (GILD) lenacapavir gets a positive CHMP opinion for the treatment of HIV-1 infection.

Gilead (GILD) HIV Candidate Gets Positive CHMP Recommendation

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences today announced that the company has signed onto the Kigali Declaration on neglected tropical diseases (NTDs) which succeeds the London Declaration on NTDs. It was launched on the margins of the Commonwealth Heads of Government Meeting (CHOGM), at a high-level session that was attended by Heads of State, other global dignitaries, industry partners and global community as part of a joint malaria and NTDs Summit. This high-level political decl

Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Neglected Tropical Diseases

A succession of HIV therapies has turned Gilead into a major pharma company; its future in HIV will be all about lenacapavir. After struggling for decades to make its mark in cancer, its TRODELVY acquisition is shaping up to be Gilead's next superstar therapy.

Gilead's Future In 3 Molecules

Biogen

BioNTech SE

Halozyme Therapeutics

IQVIA Hlds

Moderna

United Therapeutics

Biotech stocks have suffered significant setbacks during the first half of the year but are likely to bounce back soon The post 7 Biotech Stocks With Key Catalysts Coming in July appeared first on InvestorPlace. More From InvestorPlace $200 Oil Sooner Than You Think – Buy This Now The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn't matter if you have $500 in savings or $5 million.

7 Biotech Stocks With Key Catalysts Coming in July

AbbVie

Merck

These stocks offer attractive dividends that investors should be able to count on.

3 Top Dividend Stocks for Generating Passive Income

Gilead (GILD) Hepcludex meets the primary endpoint in a phase III study for the treatment of chronic hepatitis delta virus (HDV) infection at 48 weeks.

Gilead (GILD) Announces Positive Data on Hepcludex for HDV

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for investigational lenacapavir for the treatment of HIV-1 infection, in combination with other antiretroviral(s), in adults with multi-drug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen. The CHMP positive opinion i

Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV

Best Buy

Is now the time to pull the trigger on these stocks?

2 Beaten-Down Dividend Stocks That Are Now Yielding 5%

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced Week 48 results from the Pivotal Phase 3 clinical trial evaluating the first-in-class entry inhibitor Hepcludex® (bulevirtide) for the treatment of chronic hepatitis delta virus (HDV) infection. Findings from the study underscore the efficacy and safety of bulevirtide for the treatment of chronic HDV and are being presented today in the International Liver Congress™ (ILC) 2022 Official Press Program. In a

Treatment With Hepcludex® (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks

Enbridge

Simply going after the highest yields isn't a winning strategy. Companies that have the long-term growth prospects to support those dividend payouts are ideal.

Downturn Gives These 3 Buys Juicy Dividend Yields

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that more than 80 abstracts will be presented at the International Liver Congress™ (ILC) 2022, taking place from June 22-26, 2022. Key oral presentations will include Week 48 primary endpoint data from the Pivotal Phase 3 program of Hepcludex® (bulevirtide) evaluating its efficacy and safety for the treatment of hepatitis delta virus (HDV) and the impact of the treatment on patient-reported outcomes. Gilea

Gilead to Present Latest Data From Across Liver Disease Development Programs at the International Liver Congress™ 2022

Alnylam Pharmaceuticals

Baxter

Boston Scientific

Cardinal Health

Johnson & Johnson

Karuna Therapeutics Inc

Medtronic

Mirati Therapeutics

Natera

Roche Holding AG

Stryker

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

If you have the discipline to think long-term as an investor, this is the time to take advantage of the steep discounts on great biotechnology companies.

Seven reasons the beleaguered biotech sector is now a ‘buy'

This beaten-down biotech is paying a 5.1% dividend -- three times the average dividend on the S&P 500.

1 of the Safest Dividend Stocks on Earth

Arbor Realty Trust

Agnico Eagle Mines

Alico

Ally Financial

Yamana Gold

Big 5 Sporting Goods

Escalade

Fidelity National Financial

Hooker Furniture

Leggett & Platt

Lennox International

Masco

Medifast

MPLX

Pan American Silver

Prudential Financial

Sirius XM Holdings Inc

Universal Corp

Vici Properties

Whirlpool

Western Union

June 2022, The AAII Journal listed two sets of stocks sorted as: High-Yielding Dividend Payers, and Biggest Rising Dividend Payers. Those two articles revealed 40 dividend-paying-equities. The American Association of Individual Investors (AAII) is an independent non-profit corporation assisting individual investors through programs of education, information, and research.

14 June High-Yield And High-Rising Dividend Dogs Ready To Buy

Gilead Sciences, Inc. (NASDAQ:GILD ) Goldman Sachs Global Healthcare Conference June 15, 2022 2:20 PM ET Company Participants Dan O'Day - Chairman & Chief Executive Officer Merdad Parsey - Chief Medical Officer Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Good morning, everyone. Thanks so much for joining us.

Gilead Sciences, Inc. (GILD) CEO Dan O'Day Presents at Goldman Sachs Global Healthcare Conference (Transcript)

Takeda Pharmaceutical

Takeda's total debt was $35,698.6 million, down 22.1% from the previous year. Takeda Pharmaceutical has a dividend yield of 5.15%, and Gilead Sciences has a dividend yield of 4.53%.

Takeda Pharmaceutical Vs. Gilead Sciences: Who Is The Dividend King?

In trading on Tuesday, shares of Gilead Sciences were yielding above the 5% mark based on its quarterly dividend (annualized to $2.92), with the stock changing hands as low as $57.16 on the day.

Gilead Sciences Shares Cross 5% Yield Mark

GILD trades at a significant discount to its peers on an EV/EBITDA basis. The company is seeing strong growth from its HIV and oncology platforms.

Gilead: Lock In This High Yield

British American Tobacco

Devon Energy

Medical Properties Trust

Newell Brands

Simon Property Group

We got what we expected Friday, as the consumer price index came in again at levels not seen in 40 years.

7 Surprising Stocks With Fat Dividends That Offer Some Solid Inflation Protection

Gilead Sciences, Inc. (NASDAQ:GILD ) Jefferies Global Healthcare Conference June 8, 2022 11:00 AM ET Company Participants Merdad Parsey - Chief Medical Officer Conference Call Participants Michael Yee - Jefferies Michael Yee I am very happy to have up with me here on the stage, the Chief Medical Officer of Gilead Sciences, Merdad Parsey. Long time no see since I just saw you at ASCO and obviously a lot of exciting things going on in oncology for you as well and so kind of go through some of that as well as hopefully some other things, but maybe, I would just take a step back and offer you the opportunity since I think most people got the key highlights out of TRODELVY and ASCO, sort of a big picture question about how you feel about coming out of ASCO your product profile for TRODELVY, how you guys feel about where we're going?

Gilead Sciences, Inc. (GILD) Management Presents at Jefferies Global Healthcare Conference - Transcript

Comcast

Crocs

CRISPR Therapeutics

Goldman Sachs

Skyworks Solutions

Identifying oversold stocks gives investors the opportunity to buy shares that they perhaps already liked, only at a discounted price. The post 7 Oversold Stocks to Buy Right Now appeared first on InvestorPlace.

7 Oversold Stocks to Buy Right Now

News for Gilead Sciences Stock (GILD)